雷唑巴占 | 78466-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮卓类
• 中文名称: 雷唑巴占
• 中文别名: 那唑巴星
• 英文名称: Razobazam
• 英文别名: 3,8-dimethyl-4-phenyl-2H-pyrazolo[3,4-b][1,4]diazepine-5,7-dione
• CAS: 78466-98-5
• 化学式: C₁₄H₁₄N₄O₂
• 分子量: 270.29
• InChiKey: RHZDHINXKVZTEF-UHFFFAOYSA-N

物化性质

• 沸点：
  706.3±60.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• CD38-BINDING CD31 PEPTIDES AND USES THEREOF
  申请人：ENCEFA

  公开号：EP3943505A1

  公开（公告）日：2022-01-26

  The present invention relates to peptides derived from CD31, specifically binding to CD38; and their use in the prevention and/or treatment of diseases.

  本发明涉及从 CD31 衍生的肽，特别是与 CD38 结合的肽；以及它们在预防和/或治疗疾病中的用途。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Therapeutic formulations for the treatment of beta-amyloid related diseases
  申请人：Gervais Francine

  公开号：US20050031651A1

  公开（公告）日：2005-02-10

  This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.

  本发明涉及治疗淀粉样蛋白-β相关疾病（包括阿尔茨海默病）的方法和药物组合物。例如，本发明包括一种同时治疗受试者的方法，包括施用有效量的第一种药剂和第二种药剂，其中所述第一种药剂治疗淀粉样蛋白-β疾病、神经变性或细胞毒性；所述第二种药剂是治疗药物或营养补充剂。
• PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY
  申请人：SHAPIRO, Howard, K.

  公开号：EP0707446A1

  公开（公告）日：1996-04-24